SBFM Q4 2023 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M+94.9% YoY

Gross Profit

$3M33.4% margin

Operating Income

-$1M-15.5% margin

Net Income

-$1M-16.3% margin

EPS (Diluted)

$-104.69

QoQ Revenue Growth

+28.9%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$27M

Total Liabilities

$6M

Stockholders' Equity

$21M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$4M	+94.9%
Gross Profit	$3M	$1M	+72.2%
Operating Income	-$1M	-$23M	+94.9%
Net Income	-$1M	-$24M	+94.7%